Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
life sciences
national blog main
4
×
san diego blog main
san diego top stories
biotech
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
aimmune therapeutics
akcea therapeutics
allergy
alnylam pharmaceuticals
anaphylaxis
andrew oxtoby
barry greene
bial
blueprint medicines
boston
boston university
What
fda
4
×
time
4
×
approved
drug
friday
medicine
patients
add
agency
ago
aimmune
allergy
alnylam
approval
approve
awaits
awarded
biological
called
cancer
carbidopa
combination
control
crossed
daily
decades
decision
deeper
developed
discovered
disease
dna
experience
fingerprint
fingers
genetic
gets
going
historic
immunotherapy
Language
unset
Current search:
fda
×
time
×
" national blog main "
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
